Malaria in pregnancy threatens the life of both mother and child, and yet there has been very little research on how best to treat it, say a team of malaria experts in this week's PLoS Medicine.
Nicholas J. White (Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand) and colleagues describe a dangerous "catch-22" situation that prevents the health community from knowing whether new drugs, including new malaria drugs, are effective and safe in pregnancy.
"Since the disaster of thalidomide 50 years ago," they say, "the medical profession has been rightfully very cautious about giving newly developed drugs to pregnant women, for fear that they might damage the unborn baby." The result has been that new medicines often carry a prescribing caveat that they not be used in pregnancy. In fact, there may have been no worrying results from reproductive toxicology testing to warrant this caution—simply insufficient clinical information in pregnancy. Pregnant women with potentially fatal illnesses may thus be treated with inferior drugs to avoid a hypothetical risk to the unborn child, and the consequent liability.
This situation in turn leads to a "dangerous catch-22": new medicines that might be life-saving are not prescribed in pregnancy, and since they are not prescribed it is impossible to know whether they are effective and safe. Recognizing this catch-22, regulatory authorities in developed countries have begun to encourage pharmaceutical companies to gather information on the use of new drugs in pregnancy. But in the developing world, there are few or no studies in pregnancy on most drugs used for treating tropical infections such as malaria—and so there are often no recommendations for treating these infections based on good medical research.
Establishing the efficacy and safety of new malaria medicines in pregnancy should be an urgent priority, argue White and colleagues: "International agencies and funders need to provide adequate support for quality studies in pregnancy and, in an increasingly litigious climate, to underwrite the liabilities."
Source: Public Library of Science
Related stories:
Research exposes new target for malaria drugs
The malaria parasite has waged a successful guerrilla war against the human immune system for eons, but a study in this week's Journal of Biological Chemistry has exposed one of the tricks malaria uses to hide from the immune proteins, which may aid in future drug development.
Huge proportion of maternal deaths worldwide are preventable
A study published in
PLoS Medicine this week suggests that of women who die during pregnancy and childbirth in sub-Saharan Africa, more may die from treatable infectious diseases than from conditions directly linked to pregnancy.
Retinal Scans Do More Than Let You In The Door
By Courtney Ostaff
Scientists at MD Biotech in Morgantown, West Virginia, are working on “binoculars” that scan your retinas for more than just your identity. Dr. Chris Kolanko, the founder of MD Biotech, has created an Optical Scanning Instrument (OSI) that can reveal a whole host of medical problems. In the prototype, what looks like an oversized pair of binoculars scans your eye as you look through the "wrong" end. The OSI takes snapshots of the inside of your eye. Then, the snapshots are analyzed using algorithms developed from healthy and unhealthy eyes. Each algorithm evaluates small variations in eye movements, pupil size, retinal blood vessels, infections, and corneal abnormalities to determine a match to a particular illness.
Acupuncture may hold promise for women with hormone disorder
Getting pregnant with her first child was difficult, but when Rebecca Killmeyer of Charlottesville, Va. experienced a miscarriage during her second pregnancy, she wasn't sure if she would ever have another baby. When she decided to enter a study testing the impact of acupuncture on women with polycystic ovary syndrome (PCOS) at the University of Virginia Health System, she came out with a miracle.
New insight into most common forebrain malformation
St. Jude Children's Research Hospital scientists have identified one of the molecular mechanisms underlying the genetic brain malformation called holoprosencephaly (HPE). The findings not only yield insights into the most common developmental malformation of the anterior brain and face in newborns, but also help in understanding the intricate process by which the brain forms in the developing fetus.
Pre-eclampsia may be autoimmune disease
Biochemists at The University of Texas Medical School at Houston say they are the first to provide pre-clinical evidence that pregnancy-induced high blood pressure or pre-eclampsia may be an autoimmune disease. Their research could provide novel diagnostic and therapeutic possibilities for this intractable disease. Findings appear online in
Nature Medicine on July 27.
Epilepsy drug may increase risk of birth defects
Taking the epilepsy drug topiramate alone or along with other epilepsy drugs during pregnancy may increase the risk of birth defects, according to a study published in the July 22, 2008, issue of
Neurology, the medical journal of the American Academy of Neurology.
HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study
In battle with an epidemic that has outpaced nearly all efforts to contain it, researchers are turning to strategies centered on the same antiretroviral (ARV) drugs that have been used successfully to treat HIV in hopes they will be as effective a stronghold for preventing the virus.